Biotech Values

[floblu14]

Momenta Pharmaceuticals Announces Presentation of Preclinical Data on the Anti-Cancer Properties of M402 at AACR Meeting

M402, a Rationally Designed Heparin Sulfate Mimetic With a Novel Mechanism of Action, Synergizes With Gemcitabine to Improve Survival and Reduce Metastasis in a Murine Model of Pancreatic Cancer. April 19, 2010, 9:01 a.m. EDT

Key Conclusions:

-- The combination of M402 and gemcitabine significantly improved survival and substantially lowered the incidence of metastasis compared to mice treated with gemcitabine alone.
-- Mice treated with M402 showed reduced epithelial-to-mesenchymaltransition (EMT), a key step in the progression of tumor cells towards a more invasive phenotype.

http://www.marketwatch.com/story/momenta-pharmaceuticals-announces-presentation-of-preclinical-data-on-the-anti-cancer-properties-of-m402-at-aacr-meeting-2010-04-19?reflink=MW_news_stmp